STL Volume 28 Number 1
3 POSTS 0 COMMENTSPurchase PDF for $2.79
Tralokinumab is an effective and safe treatment for adult patients with moderate-to-severe AD. It may be used alone or in combination with TCS. This biologic can be considered first-line treatment after failure of or intolerance to topical therapies.
Awareness of the molecular mechanisms of antibiotic resistance among bacteria is necessary to understand the etiology of antibiotic resistance in dermatology at the most basic level.
Update covering: Deucravacitinib tablets (Sotyktu™), mRNA vaccine + pembrolizumab IV combination therapy (mRNA-4157/V940 + Keytruda®), Adalimumab-aacf SC injection (Idacio®), Dupilumab for SC injection (Dupixent®), and Spesolimab IV injection (Spevigo®).